The number of organ transplants has continued to grow over the years. Unfortunately, it seems as though supply is not going to catch up to demand any time soon.

With such a backlog of transplants, patients and clinicians alike want to ensure the safety of their new transplanted organ. Thankfully, medical diagnostic company CareDx (NASDAQ: CDNA) is working to address this issue. Let's take a look at what trends have me convinced to hold this healthcare company, despite the fact that its stock price is down more than 30% year-to-date.

Continue reading

Source Fool.com